Hosted on MSN10d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
contemporarypediatrics23d
Key atopic dermatitis approvals are changing the treatment landscape
The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms. 2024 was a big year for the atopic dermatitis (AD) ...